Pfizer Inc (PFE.N) and Merck & Co Inc (MRK.N) announced on Wednesday new trials of their experimental oral antiviral drugs for COVID-19 as the race to develop an easy-to-administer treatment for the potentially fatal illness heats up.
. . .
Pfizer's drug is designed to block the activity of a key enzyme that is needed for the coronavirus to multiply.
lees meer (Eng.)